{"id":"W3017322331","doi":"10.1016/j.jtho.2020.03.028","title":"Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":607,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System","funders":"Eli Lilly Japan; Incyte; Yuhan; F. Hoffmann-La Roche; Roche; Chugai Pharmaceutical; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atezolizumab; Medicine; Carboplatin; Hazard ratio; Internal medicine; Oncology; Population; Paclitaxel; Randomized controlled trial; Chemotherapy; Confidence interval; Cancer; Cisplatin; Pembrolizumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001461796,0.0001636324,0.001341641,0.0002555797,0.000024346,0.00001417947,0.0000858261,0.0001764545,0.00003073517],"category_scores_gemma":[0.001000303,0.0001173738,0.0001341812,0.0003386878,0.0001467933,0.0001484629,0.00001986103,0.0005053696,6.968144e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003305573,"about_ca_system_score_gemma":0.0004996843,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000285171,"about_ca_topic_score_gemma":0.000274329,"domain_scores_codex":[0.9975052,0.000536033,0.001286856,0.0002168716,0.0002605093,0.000194468],"domain_scores_gemma":[0.9977614,0.0009589323,0.0009177062,0.0001107199,0.0001108478,0.000140358],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8834155,0.0007001358,0.00007471377,0.00002041547,0.0001242182,0.0007320888,0.003635725,0.00001330379,0.005587092,0.000003947165,0.0001079348,0.105585],"study_design_scores_gemma":[0.9791423,0.01489098,0.0009992055,0.0002790974,0.0001922276,0.0001800197,0.001067058,0.0007721705,0.0009527798,0.0001237083,0.001275621,0.0001248543],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854159,0.001747725,0.0001337343,0.01072923,0.0003118078,0.001086058,0.00001501439,0.000009334781,0.0005511569],"genre_scores_gemma":[0.9974251,0.0003327277,0.001281984,0.0006891879,0.0001877444,0.00001755355,0.000016617,0.00001542497,0.00003363478],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1054601,"threshold_uncertainty_score":0.4786367,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02215734906571848,"score_gpt":0.3832901829427656,"score_spread":0.3611328338770471,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}